CoultreonBiopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.
Coultreon Biopharma has raised $125.0M in total funding. The most recent round was Series A. The last funding was announced in April 2026.
Coultreon Biopharma's investors include Balyasny Asset Management, Novo Holdings, Samsara BioCapital, Longwood Fund, Sofinnova Investments.
Coultreon Biopharma is headquartered in Heverlee, Belgium.
CoultreonBiopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.
Coultreon Biopharma is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Coultreon Biopharma — Funding & Investors." VCBacked, April 28, 2026, https://www.vcbacked.co/company/coultreon-biopharma. Accessed September 7, 2026.
VCBacked. (2026). Coultreon Biopharma — Funding & Investors. Retrieved September 7, 2026, from https://www.vcbacked.co/company/coultreon-biopharma
{{cite web |title=Coultreon Biopharma — Funding & Investors |url=https://www.vcbacked.co/company/coultreon-biopharma |website=VCBacked |access-date=September 7, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated